PGN-EDO51

What is PGN-EDO51?

PGN-EDO51 was PepGen's investigational peptide-phosphorodiamidate morpholino oligomer (PMO) conjugate designed to induce exon 51 skipping in dystrophin pre-mRNA for the treatment of Duchenne muscular dystrophy (DMD) patients with exon 51-amenable mutations (approximately 13% of DMD patients). The molecule combined PepGen's Enhanced Delivery Oligonucleotide (EDO) peptide platform — a cell-penetrating peptide designed to improve oligonucleotide delivery to skeletal and cardiac muscle — with a PMO targeting the dystrophin exon 51 splice junction, similar in target and mechanism to eteplirsen (Exondys 51, FDA-approved 2016). The program was **discontinued by PepGen in 2024** after Phase 1 dose-escalation results showed lower-than-expected exon skipping efficiency, reframing the EDO platform's near-term applicability. The entry remains in this catalog for completeness — the program illustrates the persistent challenge of muscle-targeted oligonucleotide delivery in DMD.

What PGN-EDO51 Is Investigated For

PGN-EDO51 was PepGen's lead Phase 1 program for DMD exon 51 skipping, designed to compete with eteplirsen (Exondys 51) using a cell-penetrating peptide-conjugated PMO. The 2024 Phase 1 results showed exon skipping efficiency below pre-specified thresholds, leading PepGen to discontinue the program in late 2024. The HFCRD-DM1 / PGN-EDODM1 program for myotonic dystrophy type 1 was also discontinued. PepGen has pivoted its development focus following these decisions. For DMD patients, the available approved exon-skipping therapies (eteplirsen for exon 51, golodirsen for exon 53, viltolarsen for exon 53, casimersen for exon 45) remain the established options, with subsequent peptide-mediated approaches (Vertex's VX-670 for DM1, Avidity's del-zota for DM1, others) at varying development stages.

History & Discovery

PepGen was founded around the EDO cell-penetrating peptide platform for improving oligonucleotide delivery to skeletal and cardiac muscle. PGN-EDO51 was the lead DMD candidate, and PGN-EDODM1 was the parallel myotonic dystrophy candidate. The Phase 1 dose-escalation trials in 2023–2024 produced exon skipping or DMPK reduction levels below the prespecified thresholds, and PepGen discontinued both programs in late 2024. The company has since pivoted strategically. The DMD oligonucleotide delivery problem remains unsolved at the clinical efficiency level needed for substantial dystrophin restoration. Multiple subsequent peptide-conjugate approaches (Avidity, Sarepta peptide-PMOs, others) are at varying development stages, and Vertex's VX-670 for DM1 entered Phase 1 in 2024–2025. The PepGen discontinuation underscores the technical difficulty of the muscle oligonucleotide delivery problem. Post-discontinuation, the surrounding DMD-modality field has continued to evolve in directions that further contextualize why PGN-EDO51's Phase 1 pharmacodynamic readout came in below threshold. In mdx mice, a 2026 Mol Ther Nucleic Acids study co-authored by PepGen founder M.J.A. Wood (PMID 42568847) using the same PPMO chemistry showed adult treatment achieving 79% exon skipping and 35% dystrophin restoration while aged mice fell to 44% and 8% — quantitative preclinical evidence of an age-widening restoration ceiling that plausibly underlies the class-level clinical shortfall. In parallel, the antibody-oligonucleotide conjugate (AOC) modality — Avidity's competing approach — produced NEJM Phase 1/2 data in 2026 for delpacibart etedesiran (AOC 1001) in myotonic dystrophy type 1 (PMID 41707138), meaningfully validating a delivery chemistry that has begun to displace peptide-conjugated antisense in muscle-disease programs. And a 2026 Cell paper (PMID 42269605) demonstrated durable dystrophin restoration in three DMD patients over 1.5+ years from a single AAV dose of circular arRNA-guided exon skipping (LEAPER 2.0) — a fundamentally different modality that raises the bar peptide-PMO chemistry needs to clear to justify further development. A 2026 Genes review (PMID 42510866) synthesizes the emerging picture that dystrophin-restoration magnitude and preserved ambulation do not straightforwardly correlate across the four approved exon-skippers, which further complicates what pharmacodynamic threshold a peptide-PMO like PGN-EDO51 would even need to hit for clinical benefit.

How It Works

DMD is caused by mutations in the dystrophin gene that prevent muscle cells from producing functional dystrophin protein. Exon skipping therapies use oligonucleotides to make muscle cells skip over the mutated exon during RNA processing, producing a shorter but still functional dystrophin protein. PGN-EDO51 was designed to do this for the exon 51 mutation, using a cell-penetrating peptide to deliver the oligonucleotide into muscle cells more efficiently. The approach didn't achieve enough exon skipping in Phase 1 to continue development.

PGN-EDO51 consisted of a phosphorodiamidate morpholino oligomer (PMO) targeting the dystrophin exon 51 splice junction, conjugated to PepGen's EDO cell-penetrating peptide platform. The PMO portion was mechanistically similar to eteplirsen — designed to hybridize with the splice signal at exon 51 and force exon 51 skipping during pre-mRNA processing, producing a truncated but partially functional dystrophin protein in patients with exon 51-amenable mutations. The EDO peptide was intended to improve cellular uptake of the PMO in skeletal and cardiac muscle, addressing the major limitation of naked PMO therapy (low muscle uptake). The Phase 1 readout in 2024 measured dystrophin restoration and exon skipping efficiency in muscle biopsy. The results were below the pre-specified threshold for continued development, leading to program discontinuation.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about PGN-EDO51:

• 01Why peptide-PMO conjugates have not achieved the dystrophin restoration thresholds needed for clinical benefit in DMD — a technical question relevant to ongoing peptide-oligonucleotide programs.
• 02Whether the EDO platform can be optimized for other oligonucleotide targets or whether the fundamental approach faces a ceiling.
• 03How the age-widening dystrophin-restoration ceiling seen in mdx-mouse PPMO studies (PMID 42568847: 35% restoration in adults, 8% in aged mice) maps onto the human clinical trial ages and disease-severity distributions that Phase 1 programs enrol.
• 04Whether the AOC modality's early clinical validation in DM1 (delpacibart etedesiran, PMID 41707138) will generalize to DMD exon-skipping, which would further reduce the addressable space for peptide-PMO programs.
• 05How to reconcile the loose correlation between dystrophin-restoration magnitude and preserved ambulation across the four approved exon-skippers (PMID 42510866) — the answer determines what pharmacodynamic bar a peptide-PMO revival would need to clear.

Forms & Administration

Was IV infusion in Phase 1 trials. Not commercially available — program discontinued.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Program discontinued; not available.

Timeline of Effects

Common Questions

Who PGN-EDO51 Is NOT For

Drug & Supplement Interactions

Not characterized. Program discontinued.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions